Merck, Inc.
Efficacy, Immunogenicity, and Safety Study of the 9vHPV Vaccine in Japanese Males (V503-064)
- Conditions
- Neoplasms, AnalWarts, Genital
- Interventions
- Other: Placebo
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1059
- Registration Number
- NCT04635423
- Locations
- 🇯🇵
Kanno Clinic ( Site 6402), Sakai, Osaka, Japan
🇯🇵Seiyukai Medical Corporation Itoh Skin Clinic ( Site 6416), Tokyo, Japan
🇯🇵P-One Clinic, Keikokai Medical Corp. ( Site 6419), Hachioji, Tokyo, Japan
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
- Conditions
- Endometrial Neoplasms
- Interventions
- Radiation: External Beam Radiotherapy (EBRT)Radiation: Brachytherapy
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 990
- Registration Number
- NCT04634877
- Locations
- 🇨🇦
Kingston Health Sciences Centre ( Site 3003), Kingston, Ontario, Canada
🇺🇸University of South Alabama, Mitchell Cancer Institute ( Site 3058), Mobile, Alabama, United States
🇺🇸WK Physicians Network/Gynecologic Oncology Associates ( Site 3047), Shreveport, Louisiana, United States
Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036)
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 58
- Registration Number
- NCT04633226
- Locations
- 🇰🇷
Jeonbuk National University Hospital ( Site 0008), Jeonju-si, Jeonrabugdo, Korea, Republic of
🇰🇷Hallym University Dongtan Sacred Heart Hospital ( Site 0013), Hwaseong-si, Kyonggi-do, Korea, Republic of
🇰🇷CHA Bundang Medical Center CHA University ( Site 0020), Seongnam si, Kyonggi-do, Korea, Republic of
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
- Conditions
- Carcinoma, Renal Cell
- Interventions
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 370
- Registration Number
- NCT04626518
- Locations
- 🇺🇸
UTSW Medical Center ( Site 3003), Dallas, Texas, United States
🇺🇸University of Chicago ( Site 3013), Chicago, Illinois, United States
🇺🇸Yale-New Haven Hospital-Yale Cancer Center ( Site 3011), New Haven, Connecticut, United States
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
- Conditions
- Carcinoma, Renal Cell
- Interventions
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 400
- Registration Number
- NCT04626479
- Locations
- 🇳🇱
Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)-medical oncology ( Site 2402), Amsterdam, Noord-Holland, Netherlands
🇨🇱CIDO SpA-Oncology ( Site 2106), Temuco, Araucania, Chile
🇬🇧The Christie NHS Foundation Trust ( Site 1400), Manchester, United Kingdom
Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 500
- Registration Number
- NCT04624243
- Locations
- 🇺🇸
Pillar Clinical Research, LLC ( Site 1038), Chicago, Illinois, United States
🇺🇸Richmond Behavioral Associates ( Site 1064), Staten Island, New York, United States
🇺🇸Massachusetts General Hospital ( Site 1035), Boston, Massachusetts, United States
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
- Conditions
- Small Cell Lung Cancer
- Interventions
- Drug: Platinum, investigator's choiceRadiation: Standard Thoracic RadiotherapyRadiation: Prophylactic Cranial Irradiation (PCI)
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 672
- Registration Number
- NCT04624204
- Locations
- 🇺🇸
Fairview Hospital-Moll Cancer Center ( Site 0141), Cleveland, Ohio, United States
🇺🇸Cleveland Clinic Main ( Site 0139), Cleveland, Ohio, United States
🇺🇸MD Anderson Cancer Center ( Site 0100), Houston, Texas, United States
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
- Conditions
- Carcinoma, Renal Cell
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 708
- Registration Number
- NCT04586231
- Locations
- 🇺🇸
Confluence Health | Wenatchee Valley Hospital & Clinics ( Site 0061), Wenatchee, Washington, United States
🇺🇸Georgetown University Medical Center ( Site 0006), Washington, District of Columbia, United States
🇺🇸Memorial Sloan Kettering Cancer Center ( Site 0055), New York, New York, United States
A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)
- First Posted Date
- 2020-10-12
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 183
- Registration Number
- NCT04583423
- Locations
- 🇺🇸
Del Sol Research Management ( Site 2674), Tucson, Arizona, United States
🇺🇸Adobe Clinical Research, LLC ( Site 2644), Tucson, Arizona, United States
🇺🇸Hope Clinical Research, Inc. ( Site 2601), Canoga Park, California, United States
Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)
- Conditions
- Coronavirus Disease (COVID-19)
- Interventions
- Drug: MolnupiravirDrug: Placebo
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 304
- Registration Number
- NCT04575584
- Locations
- 🇺🇸
Temple University ( Site 1836), Philadelphia, Pennsylvania, United States
🇲🇽Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0800), Guadalajara, Jalisco, Mexico
🇺🇦MNE Ivano-Frankivsk Regional Phthisiology-Pulmonology Center ( Site 1603), Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine